

- Ingenol mebutate (Picato[®], LEO Pharma A/S, Ballerup, Denmark) is a newly approved topical field therapy for actinic keratosis.
- It has a dual mechanism of action, inducing rapid cellular necrosis of dysplastic keratinocytes as well as stimulating neutrophil mediated antibody-dependent-cellular-cytotoxicity (ADCC).
- It is this dual mechanism of action that allows this agent to produce similar outcomes to other field therapies in a much shorter duration of application.
- A number of trials have highlighted that this shorter period of application reduces any potential side effects that may occur.
- Ingenol mebutate is proving to have a place alongside other field therapies such as imiquimod, diclofenac and 5-fluorouracil, as an effective treatment for actinic keratosis.

This summary slide represents the opinions of the authors. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Authors 2014. Creative Commons Attribution Noncommercial License (CC BY-NC).